171 related articles for article (PubMed ID: 11903325)
1. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat.
Ficai S; Herizi A; Mimran A; Jover B
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1100-3. PubMed ID: 11903325
[TBL] [Abstract][Full Text] [Related]
2. [Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan].
Herizi A; Belabbas H; Mimran A; Jover B
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):983-6. PubMed ID: 10989742
[TBL] [Abstract][Full Text] [Related]
3. [Bosentan attenuates the hypertensive effect of angiotensin II in rats].
Herizi A; Jover B; Mimran A
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1117-20. PubMed ID: 9404419
[TBL] [Abstract][Full Text] [Related]
4. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.
Herizi A; Jover B; Bouriquet N; Mimran A
Hypertension; 1998 Jan; 31(1):10-4. PubMed ID: 9449383
[TBL] [Abstract][Full Text] [Related]
5. Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan.
Fraser TB; Mangos GJ; Turner SW; Whitworth JA
Clin Exp Pharmacol Physiol; 1999 Aug; 26(8):628-33. PubMed ID: 10474778
[TBL] [Abstract][Full Text] [Related]
6. Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.
Hara K; Kobayashi N; Nakano S; Mori Y; Tsubokou Y; Matsuoka H
Hypertens Res; 2001 Jan; 24(1):55-64. PubMed ID: 11213031
[TBL] [Abstract][Full Text] [Related]
7. Bosentan prevents preglomerular alterations during angiotensin II hypertension.
Casellas D; Bouriquet N; Herizi A
Hypertension; 1997 Dec; 30(6):1613-20. PubMed ID: 9403591
[TBL] [Abstract][Full Text] [Related]
8. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Rossi GP; Sacchetto A; Rizzoni D; Bova S; Porteri E; Mazzocchi G; Belloni AS; Bahcelioglu M; Nussdorfer GG; Pessina AC
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):949-56. PubMed ID: 10764658
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor blockade unmasks a depressor response to endothelin antagonists in rats.
Richard V; Hogie M; Thuillez C
Fundam Clin Pharmacol; 2000; 14(2):101-6. PubMed ID: 10796056
[TBL] [Abstract][Full Text] [Related]
11. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates.
Bartholomeusz B; Hardy KJ; Nelson AS; Phillips PA
Hypertension; 1996 Jun; 27(6):1341-5. PubMed ID: 8641746
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.
Kaddoura S; Firth JD; Boheler KR; Sugden PH; Poole-Wilson PA
Circulation; 1996 Jun; 93(11):2068-79. PubMed ID: 8640984
[TBL] [Abstract][Full Text] [Related]
13. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats.
Dvorák P; Kramer HJ; Bäcker A; Malý J; Kopkan L; Vanecková I; Vernerová Z; Opocenský M; Tesar V; Bader M; Ganten D; Janda J; Cervenka L
Kidney Blood Press Res; 2004; 27(4):248-58. PubMed ID: 15286437
[TBL] [Abstract][Full Text] [Related]
14. Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats.
De Smet HR; Menadue MF; Oliver JR; Phillips PA
Clin Exp Pharmacol Physiol; 2003 Apr; 30(4):278-83. PubMed ID: 12680847
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.
Vanourková Z; Kramer HJ; Erbanová M; Bäcker A; Cervenka L; Husková Z; Chábová VC; Tesar V; Dvorák P; Malý J; Vanecková I
Vascul Pharmacol; 2009; 50(5-6):194-9. PubMed ID: 19563737
[TBL] [Abstract][Full Text] [Related]
16. Contrasting effects of intervention with ETA and ETB receptor antagonists in hypertension induced by angiotensin II and high-salt diet.
Boesen EI; Pollock JS; Pollock DM
Can J Physiol Pharmacol; 2010 Aug; 88(8):802-7. PubMed ID: 20725138
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan.
Larivière R; Sventek P; Thibault G; Schiffrin EL
Can J Physiol Pharmacol; 1995 Mar; 73(3):390-8. PubMed ID: 7544236
[TBL] [Abstract][Full Text] [Related]
18. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
19. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Seccia TM; Belloni AS; Kreutz R; Paul M; Nussdorfer GG; Pessina AC; Rossi GP
J Am Coll Cardiol; 2003 Feb; 41(4):666-73. PubMed ID: 12598081
[TBL] [Abstract][Full Text] [Related]
20. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
